Immunic, Inc. - Common Stock (IMUX)

While speculative ideas are treacherous, you can possibly reduce your blood pressure with these penny stocks with insider buying.

Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day

Immunic chief medical officer discusses promising treatments to mark World IBD Day

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day

IMUX stock results show that Immunic missed analyst estimates for earnings per share the first quarter of 2024.

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

--News Direct--

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

--News Direct--

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

--News Direct--

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.

Immunic Inc (NASDAQ: IMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with 

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.

It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning!

--News Direct--